Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7463.09 | 0.9037 | 0.6626 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7463.09 | 0.7424 | 0.1618 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7463.09 | 0.0089 | -0.9996 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7463.09 | 0.0048 | -0.9999 | 0.5483 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7464.09 | 1.0084 | 1.0338 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7464.09 | 1.0620 | 1.2581 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7464.09 | 1.0294 | 1.1203 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7464.09 | 0.9827 | 0.9307 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7464.09 | 1.0657 | 1.2741 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7464.09 | 0.9274 | 0.7178 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7464.09 | 0.7566 | 0.1394 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7464.09 | 0.0139 | -0.9996 | 0.4958 | |
| HCC2185 | TNBC | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7464.09 | 0.0078 | -0.9999 | 0.4958 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7465.092 | 0.9339 | 0.8896 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7465.092 | 0.9201 | 0.8665 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7465.092 | 0.8534 | 0.7536 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7465.092 | 0.9062 | 0.8430 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7465.092 | 0.9656 | 0.9427 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7465.092 | 0.8333 | 0.7192 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7465.092 | 0.7985 | 0.6594 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7465.092 | 0.0634 | -0.7972 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7465.092 | 0.0046 | -0.9769 | 1.2055 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7466.092 | 0.9838 | 0.9645 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7466.092 | 0.9817 | 0.9602 | 0.9158 | |
| HCC3153 | TNBC | Basal A | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7466.092 | 1.0006 | 1.0013 | 0.9158 |